OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Korea S.E. Other stock markets 07/04/2025			5-day change	1st Jan Change
1,651.00 ^KRW	-13.92%		-.--%	-

29/12	OLIPASS Corporation announced that it has received KRW 600 million in funding	CI
18/12	OLIPASS Corporation announced that it expects to receive KRW 600 million in funding	CI

Market Cap	2.65TCr 1.73Cr 1.51Cr 1.39Cr 1.3Cr 2.44Cr 163.02Cr 2.46Cr 17Cr 6.45Cr 80Cr 6.48Cr 6.34Cr 278.44Cr	P/E 2021	-10.8x	P/E 2022	-7.66x
Enterprise Value	2.03TCr 1.32Cr 1.16Cr 1.07Cr 99.75L 1.87Cr 124.96Cr 1.89Cr 13Cr 4.94Cr 61Cr 4.96Cr 4.86Cr 213.43Cr	EV / Sales 2021	295x	EV / Sales 2022	79x
Free-Float	48.85%	Yield 2021 *	-	Yield 2022	-

29/12	OLIPASS Corporation announced that it has received KRW 600 million in funding	CI
18/12	OLIPASS Corporation announced that it expects to receive KRW 600 million in funding	CI
08/12	OLIPASS Corporation announced that it has received KRW 739 million in funding from Genocure Co., Ltd. and other investors.	CI
28/11	OLIPASS Corporation announced that it expects to receive KRW 739 million in funding from Genocure Co., Ltd. and other investors	CI
21/11	OLIPASS Corporation announced that it has received KRW 600 million in funding from Genocure Co., Ltd.	CI
13/11	OLIPASS Corporation announced that it expects to receive KRW 600 million in funding from Genocure Co., Ltd.	CI
25/25/25	OLIPASS Corporation cancelled the transaction announced on December 6, 2024	CI
01/25/01	OLIPASS Corporation announced that it has received KRW 2 billion in funding	CI
31/25/31	OLIPASS Corporation announced that it expects to receive KRW 2 billion in funding	CI
27/24/27	OLIPASS Corporation announced that it has received KRW 3.0000031 billion in funding from Invest Partners No. 1	CI
06/24/06	OLIPASS Corporation announced that it expects to receive KRW 19.99998708 billion in funding	CI
13/24/13	OLIPASS Corporation announced that it expects to receive KRW 3.0000031 billion in funding from Invest Partners No. 1	CI
28/24/28	OLIPASS Corporation announced that it has received KRW 5.500000471 billion in funding from Infraflex Ltd, Thecity Co., Ltd., Optimum New Growth Fund	CI

3 years	1,568	34,500
5 years	1,568	1,58,000
10 years	1,568	2,40,666.67

OLIPASS Corporation Share Price

Stocks

A244460

KR7244460002

Biotechnology & Medical Research

Valuation: OLIPASS Corporation

Latest news : OLIPASS Corporation

Quotes and Performance

Course Extremes

Managers and Directors: OLIPASS Corporation

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Tae-Hyun Kim CEO	Chief Executive Officer	54	22/05/2025
Bo-Kyung Oh PRN	Corporate Officer/Principal	34	28/11/2024
Ki-Won Son AUD	Comptroller/Controller/Auditor	67	31/03/2025

Director	Title	Age	Since
Tae-Hyun Kim BRD	Director/Board Member	54	28/11/2024
Bo-Kyung Oh BRD	Director/Board Member	34	28/11/2024
Young-Kwang Nam BRD	Director/Board Member	66	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OLIPASS CORPORATION	-13.92%	-.--%	-.--%	-89.99%	91.07L
ARGENX SE	-0.03%	+5.32%	+70.82%	+119.16%	5.67TCr
WUXI APPTEC CO., LTD.	+4.00%	+7.51%	+63.67%	+68.77%	4.75TCr
BIONTECH SE	-0.77%	-0.67%	-15.34%	-15.95%	2.28TCr
INSMED INCORPORATED	+2.93%	+1.17%	-3.97%	+384.78%	2.14TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.30%	+3.73%	+27.10%	-17.51%	1.61TCr
GENMAB A/S	+1.28%	+7.71%	+23.87%	-35.98%	1.56TCr
EXELIXIS, INC.	-1.08%	-3.11%	+27.20%	+158.30%	1.29TCr
PHARMAESSENTIA CORPORATION	+3.30%	+15.02%	+133.24%	+273.89%	1.29TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.43%	-6.44%	+21.49%	-	1.17TCr
Average	-0.15%	-2.65%	+34.81%	+93.94%	2.17TCr
Weighted average by Cap.	+1.48%	+3.27%	+44.72%	+109.82%

	2021	2022
Net sales	85Cr 6L 5L 4L 4L 8L 5.23Cr 8L 53.19L 20.7L 2.57Cr 20.79L 20.34L 8.94Cr	229.6Cr 14.93L 13.05L 12.07L 11.26L 21.14L 14Cr 21.3L 1.43Cr 55.79L 6.94Cr 56.05L 54.84L 24Cr
Net income	-2.51TCr -1.63Cr -1.43Cr -1.32Cr -1.23Cr -2.31Cr -154.44Cr -2.33Cr -16Cr -6.11Cr -76Cr -6.14Cr -6Cr -263.79Cr	-2.42TCr -1.57Cr -1.37Cr -1.27Cr -1.19Cr -2.23Cr -148.5Cr -2.24Cr -15Cr -5.87Cr -73Cr -5.9Cr -5.77Cr -253.64Cr
Net Debt	-1.83TCr -1.19Cr -1.04Cr -96.13L -89.72L -1.68Cr -112.39Cr -1.7Cr -11Cr -4.44Cr -55Cr -4.47Cr -4.37Cr -191.96Cr	-619.5Cr -40.28L -35.2L -32.56L -30.39L -57.05L -38Cr -57.47L -3.87Cr -1.51Cr -19Cr -1.51Cr -1.48Cr -65Cr